The clinical trial studies the human pathogen of SARS-CoV-2, with a specificity in the
circulating Spike 2 protein in the human system. The clinical trial hypothesizes that
SARS-CoV-2 human pathogen arises from immune attacks, underlying the severe physiological
symptoms that can be lethal. It further hypothesizes that the vaccines do not deal with the
Spike 2 protein that causes the immune attacks.